Trial intelligence / Profile preview

SBRT plus Checkpoint Inhibitors in Solid Tumors (CHEERS)

NCT03511391Phase 2Completed

Sponsor: Ghent University Hospital
Start: Mar 2018
Primary completion: Feb 2022
Modality: Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
Countries: 1

Overview

A Phase 2 trial of nivolumab, pembrolizumab, atezolizumab in non-small cell lung cancer (NSCLC), urothelial carcinoma (UC), renal cell carcinoma (RCC), melanoma, head and neck squamous cell carcinoma (HNSCC), sponsored by Ghent University Hospital. Started Mar 2018; status: completed.

Drugs

nivolumabpembrolizumabatezolizumab

Conditions

non-small cell lung cancer (NSCLC)urothelial carcinoma (UC)renal cell carcinoma (RCC)melanomahead and neck squamous cell carcinoma (HNSCC)

Beyond the preview

Go deeper on NCT03511391.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT03511391.